Abstract
For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Current Topics in Medicinal Chemistry
Title:Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds
Volume: 21 Issue: 30
Author(s): Hayrettin O. Gulcan*Ilkay E. Orhan*
Affiliation:
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10,Turkey
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara,Turkey
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Abstract: For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Export Options
About this article
Cite this article as:
Gulcan O. Hayrettin *, Orhan E. Ilkay *, Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds, Current Topics in Medicinal Chemistry 2021; 21 (30) . https://dx.doi.org/10.2174/1568026621666210902121148
DOI https://dx.doi.org/10.2174/1568026621666210902121148 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sialic Acid and the Central Nervous System: Perspectives on Biological Functions, Detection, Imaging Methods and Manipulation
CNS & Neurological Disorders - Drug Targets Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes
CNS & Neurological Disorders - Drug Targets Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design G-Protein-Coupled Receptors Oligomerization: Emerging Signaling Units and New Opportunities for Drug Design
Current Protein & Peptide Science Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Restless Leg Syndrome Associated with Olanzapine: A Case Series
Current Drug Safety Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Nanotubes at Neural and Immune Synapses
Current Medicinal Chemistry Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents Targeting the Central Nervous System with Herpes Simplex Virus / Sleeping Beauty Hybrid Amplicon Vectors
Current Gene Therapy